Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

被引:35
|
作者
Brims, Fraser [1 ,2 ,3 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA 6845, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia
[3] Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia
关键词
mesothelioma; asbestos; epidemiology; pleural disease; TO-LYMPHOCYTE RATIO; PROGNOSTIC-FACTORS; OPEN-LABEL; TALC PLEURODESIS; LUNG-CANCER; SOLUBLE MESOTHELIN; SERUM MESOTHELIN; PHASE-III; DIAGNOSIS; ASBESTOS;
D O I
10.3390/cancers13164194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Malignant pleural mesothelioma
    Chen, Sheree E.
    Pace, Makala B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (05) : 377 - 385
  • [32] Malignant Pleural Mesothelioma
    Siva Raja
    Sudish C. Murthy
    David P. Mason
    Current Oncology Reports, 2011, 13 : 259 - 264
  • [33] Malignant Pleural Mesothelioma
    Bois, Melanie C.
    Lee, Hee Eun
    Erickson, Lori A.
    MAYO CLINIC PROCEEDINGS, 2016, 91 (07) : E103 - E104
  • [34] Malignant pleural mesothelioma
    Pass, HI
    Vogelzang, NJ
    Hahn, S
    Carbone, M
    CURRENT PROBLEMS IN CANCER, 2004, 28 (03) : 85 - +
  • [35] Malignant pleural mesothelioma
    Gross-Goupil, M
    Ruffié, P
    BULLETIN DU CANCER, 1999, : 43 - 54
  • [36] Malignant Pleural Mesothelioma
    Tsao, Anne S.
    Wistuba, Ignacio
    Roth, Jack A.
    Kindler, Hedy Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) : 2081 - 2090
  • [37] MALIGNANT PLEURAL MESOTHELIOMA
    GEROULANOS, S
    HAEFNER, F
    SENNING, A
    LARGIADER, F
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1987, : 24 - 24
  • [38] Malignant pleural mesothelioma
    Stahel, Rolf A.
    Felley-Bosco, Emanuela
    Opitz, Isabelle
    Weder, Walter
    FUTURE ONCOLOGY, 2009, 5 (03) : 391 - 402
  • [39] Malignant pleural mesothelioma
    Boutin, C
    Schlesser, M
    Frenay, C
    Astoul, P
    EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (04) : 972 - 981
  • [40] Malignant Pleural Mesothelioma
    Ettinger, David S.
    Akerley, Wallace
    Borghaei, Hossein
    Chang, Andrew
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Demmy, Todd L.
    Ganti, Apar Kishor P.
    Govindan, Ramaswamy
    Grannis, Frederic W., Jr.
    Horn, Leora
    Jahan, Thierry M.
    Jahanzeb, Mohammad
    Kessinger, Anne
    Komaki, Ritsuko
    Kong, Feng-Ming
    Kris, Mark G.
    Krug, Lee M.
    Lennes, Inga T.
    Loo, Billy W., Jr.
    Martins, Renato
    O'Malley, Janis
    Osarogiagbon, Raymond U.
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pinder-Schenck, Mary
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Rohren, Eric
    Swanson, Scott J.
    Wood, Douglas E.
    Yang, Stephen C.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (01): : 26 - 41